These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26289547)

  • 61. Taking forward the World TB Day 2016 theme 'Unite to End Tuberculosis' for the WHO Africa Region.
    Ntoumi F; Kaleebu P; Macete E; Mfinanga S; Chakaya J; Yeboah-Manu D; Bates M; Mwaba P; Maeurer M; Petersen E; Zumla A
    Int J Infect Dis; 2016 May; 46():34-7. PubMed ID: 26969406
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Management of multidrug-resistant tuberculosis in the 21st century.
    Kaul G; Kapoor E; Dasgupta A; Chopra S
    Drugs Today (Barc); 2019 Mar; 55(3):215-224. PubMed ID: 30938375
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The global situation of MDR-TB.
    Espinal MA
    Tuberculosis (Edinb); 2003; 83(1-3):44-51. PubMed ID: 12758188
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Managing multiple and extensively drug-resistant tuberculosis and HIV.
    Padayatchi N; Friedland G
    Expert Opin Pharmacother; 2007 Jun; 8(8):1035-7. PubMed ID: 17516869
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Heightened vulnerability to MDR-TB epidemics after controlling drug-susceptible TB.
    Bishai JD; Bishai WR; Bishai DM
    PLoS One; 2010 Sep; 5(9):e12843. PubMed ID: 20877639
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Personalized medicine for patients with MDR-TB.
    Olaru ID; Lange C; Heyckendorf J
    J Antimicrob Chemother; 2016 Apr; 71(4):852-5. PubMed ID: 26507429
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Limited access to drugs for resistant tuberculosis: a call to action.
    Bélard S; Janssen S; Osbak KK; Adegnika AA; Ondounda M; Grobusch MP
    J Public Health (Oxf); 2015 Dec; 37(4):691-3. PubMed ID: 25527468
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Scenario Analysis for Programmatic Tuberculosis Control in Western Province, Papua New Guinea.
    Trauer JM; Denholm JT; Waseem S; Ragonnet R; McBryde ES
    Am J Epidemiol; 2016 Jun; 183(12):1138-48. PubMed ID: 27199387
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Use of Transnational Services to Prevent Treatment Interruption in Tuberculosis-Infected Persons Who Leave the United States.
    Tschampl CA; Garnick DW; Zuroweste E; Razavi M; Shepard DS
    Emerg Infect Dis; 2016 Mar; 22(3):417-25. PubMed ID: 26886720
    [TBL] [Abstract][Full Text] [Related]  

  • 70. 'Universal' access for MDR-TB limited without the involvement of the private sector.
    Pinto L; Udwadia Z
    Int J Tuberc Lung Dis; 2011 Jun; 15(6):851; author reply 851-2. PubMed ID: 21575312
    [No Abstract]   [Full Text] [Related]  

  • 71. Clinical implications of the global multidrug-resistant tuberculosis epidemic.
    Kumar K; Abubakar I
    Clin Med (Lond); 2015 Dec; 15 Suppl 6():s37-42. PubMed ID: 26634680
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Insights into the pharmacokinetic properties of antitubercular drugs.
    Shukla M; Sharma A; Jaiswal S; Lal J
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):765-78. PubMed ID: 27120703
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Challenging MDR-TB clinical problems - The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs.
    Tiberi S; Pontali E; Tadolini M; D'Ambrosio L; Migliori GB
    Int J Infect Dis; 2019 Mar; 80S():S68-S72. PubMed ID: 30690212
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Drug-Resistant tuberculosis - primary transmission and management.
    Outhred AC; Britton PN; Marais BJ
    J Infect; 2017 Jun; 74 Suppl 1():S128-S135. PubMed ID: 28646952
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ethical issues in tuberculosis diagnosis and treatment.
    Selgelid MJ; Reichman LB
    Int J Tuberc Lung Dis; 2011 Jun; 15 Suppl 2():9-13. PubMed ID: 21740653
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Procurement and Supply Management System for MDR-TB in Nigeria: Are the Early Warning Targets for Drug Stock Outs and Over Stock of Drugs Being Achieved?
    Jatau B; Avong Y; Ogundahunsi O; Shah S; Tayler Smith K; Van den Bergh R; Zachariah R; van Griensven J; Ekong E; Dakum P
    PLoS One; 2015; 10(6):e0128500. PubMed ID: 26098673
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Programmatic versus personalised approaches to managing the global epidemic of multidrug-resistant tuberculosis.
    Chakaya JM; Marais B; du Cros P; Ntoumi F; Mfinanga S; Kapata N; Hasnain SE; Nathavitharana R; Zumla A
    Lancet Respir Med; 2020 Apr; 8(4):334-335. PubMed ID: 32113573
    [No Abstract]   [Full Text] [Related]  

  • 78. Drug-resistant tuberculosis in Africa.
    Mwinga A
    Ann N Y Acad Sci; 2001 Dec; 953():106-12. PubMed ID: 11795401
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Association between diabetes mellitus and multi-drug-resistant tuberculosis: a protocol for a systematic review and meta-analysis.
    Tegegne BS; Habtewold TD; Mengesha MM; Burgerhof JG
    Syst Rev; 2017 Jan; 6(1):6. PubMed ID: 28088237
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis.
    Kendall EA; Fofana MO; Dowdy DW
    Lancet Respir Med; 2015 Dec; 3(12):963-72. PubMed ID: 26597127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.